100+ Free Medical Oncology SCE Practice Questions

Breast cancer

Early and metastatic breast cancer, receptor-directed therapy, HER2 treatment, endocrine therapy, triple-negative disease, genetics, bone metastases, and survivorship.

Colorectal and anal cancer

Colon, rectal, and anal cancer staging and systemic treatment, RAS/BRAF/MMR biomarkers, neoadjuvant rectal strategies, adjuvant chemotherapy, and chemoradiotherapy for anal cancer.

Lung and thoracic cancer

NSCLC and SCLC diagnosis, staging, molecular testing, PD-L1, targeted therapy, immunotherapy, chemoradiotherapy, pleural disease, and thoracic emergencies.

Carcinoma of unknown origin

CUP work-up, immunohistochemistry, molecular testing, favourable subsets, symptom-led management, and site-specific versus empirical treatment decisions.

Ovarian cancer

High-grade serous ovarian cancer, cytoreduction decisions, platinum sensitivity, BRCA and HRD testing, PARP maintenance, relapse assessment, and CA125 limitations.

Germ cell tumours

Testicular and ovarian germ cell tumours, AFP and hCG interpretation, seminoma versus non-seminoma, cisplatin-based curative treatment, and late toxicities.

Oesophagogastric cancer

Oesophageal, gastro-oesophageal junction, and gastric adenocarcinoma, perioperative chemotherapy, HER2, PD-L1 and MMR testing, nutrition, and staging.

Lymphoma

Oncology-haematology overlap, urgent recognition of lymphoma presentations, DLBCL referral, tumour lysis risk, and steroid timing before tissue diagnosis.

Uterine cancer

Endometrial cancer risk stratification, mismatch repair testing, recurrent disease systemic therapy, immunotherapy, and multidisciplinary gynaecological oncology care.

Hepatobiliary cancer

Hepatocellular carcinoma, cholangiocarcinoma, liver function assessment, portal hypertension, immunotherapy-bevacizumab, FGFR2 and IDH1 targets, and biliary obstruction.

Skin cancer

Melanoma, cutaneous squamous cell carcinoma, BRAF testing, anti-PD-1 therapy, BRAF/MEK inhibition, adjuvant treatment, and immune toxicity.

Sarcoma

Soft-tissue sarcoma, GIST, bone sarcoma, desmoid tumour, specialist sarcoma MDT referral, doxorubicin, imatinib, and biopsy planning.

Leukaemia

Haematology overlap including urgent recognition of acute promyelocytic leukaemia, coagulopathy, tumour lysis, and need for immediate specialist referral.

Prostate cancer

Hormone-sensitive and castration-resistant prostate cancer, ADT intensification, AR pathway inhibitors, docetaxel, PARP selection, bone disease, and spinal cord compression.

Urothelial cancer

Cisplatin eligibility, platinum and immunotherapy pathways, antibody-drug conjugates, FGFR alteration testing, haematuria assessment, and supportive care.

Cervical cancer

HPV-related disease, staging, concurrent cisplatin chemoradiotherapy, brachytherapy, recurrent disease options, and toxicity management.

Head and neck cancer

Squamous head and neck cancer, HPV and p16 status, smoking risk, chemoradiotherapy, immunotherapy in recurrent disease, nutrition, and airway risk.

CNS cancer

Glioblastoma, MGMT promoter methylation, brain metastases, steroids, seizure management, local therapy, and neurologic emergencies.

Renal cell cancer

Clear-cell RCC, risk stratification, immune checkpoint combinations, VEGF TKIs, cytoreductive nephrectomy decisions, and toxicity trade-offs.

Endocrine cancer

Thyroid and neuroendocrine tumours, RET alterations, somatostatin receptor imaging, somatostatin analogues, PRRT, and hormonal syndromes.

Scientific basis of malignancy

Tumour biology, genomics, DNA repair, biomarkers, targeted therapy, immunotherapy mechanisms, pathology interpretation, response criteria, and ctDNA.

Professional skills

Shared decision-making, consent, capacity, communication, MDT working, training, supervision, quality improvement, patient safety, and ethical practice.

Acute oncology

Neutropenic sepsis, spinal cord compression, SVC obstruction, hypercalcaemia, tumour lysis, brain metastases, bowel obstruction, immunotherapy emergencies, CRS, and DIC.

Clinical research, ethics and economics

Clinical trial phases, randomisation, non-inferiority, bias, hazard ratios, Kaplan-Meier analysis, NNT, GCP, adverse event reporting, and consent.

Systemic anticancer therapy

Chemotherapy, endocrine therapy, targeted therapy, immunotherapy, CAR-T interface, dosing, extravasation, hypersensitivity, pneumonitis, cardiotoxicity, and safe prescribing.

Supportive therapies and palliative care

Antiemetics, G-CSF, cancer pain, renal impairment, palliative care integration, malignant bowel obstruction, bone metastases, fertility, survivorship, and late effects.

Standard operating procedures

SACT governance, local protocols, pharmacy review, staff training, toxicity escalation pathways, consent documentation, audit, and implementation of new treatments.